ValiRx Plc (LON:VAL)‘s stock had its “speculative buy” rating reaffirmed by stock analysts at Beaufort Securities in a research report issued to clients and investors on Friday. They presently have a GBX 6.50 ($0.09) price objective on the stock.
ILLEGAL ACTIVITY WARNING: This story was posted by Community Financial News and is the sole property of of Community Financial News. If you are accessing this story on another publication, it was illegally stolen and reposted in violation of US and international trademark and copyright law. The legal version of this story can be read at https://www.com-unik.info/2017/10/13/valirx-plcs-val-speculative-buy-rating-reaffirmed-at-beaufort-securities.html.
ValiRx Plc Company Profile
ValiRx plc is a biopharmaceutical company. The principal activity of the Company is the development of oncology therapeutics and companion diagnostics. It focuses on the treatment of cancer and associated biomarkers, specializing in epigenomic and genetic analysis. It operates in two business segments: drug development and the sale of self-test drug kits.
What are top analysts saying about ValiRx Plc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for ValiRx Plc and related companies.